A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Azacitidine Injection

On the basis of the conventional transplantation treatment regimen, combining azacitidine injection with BUCY2 conditioning regimen (azacitidine 75 mg/m2/d for -11 days to -5 days, cytarabine 2 g/m2 q12h for -8 days to -7 days, cyclophosphamide 1.8 g/m2/d for -6 days to -5 days, busulfan 3.2 mg/kg/d for -4 days to -2 days)

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06279338 - A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score | Biotech Hunter | Biotech Hunter